ESC 365 - Increasing use of NOAC and antiplatelet combination therapy in atrial fibrillation following myocardial infarction or percutaneous coronary intervention

ESC Premium Access

Increasing use of NOAC and antiplatelet combination therapy in atrial fibrillation following myocardial infarction or percutaneous coronary intervention

Session: Drug treatment in patients with arrhythmia

Topic: Antiarrhythmic drugs

Speaker: Ms C. Clausen (Hellerup, DK)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Ms Caroline Sindet Clausen

Gentofte Hospital - Copenhagen University Hospital, Hellerup (Denmark)

0 follower

7 more presentations in this session

Association between sociodemographic factors and choice of Direct Oral Anticoagulants versus warfarin in atrial fibrillation: A population based cross-sectional study using Swedish Registers

Speaker: Mr G. Brobert (Solna, SE)

Favorable effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with liver cirrhosis

Speaker: Doctor H. Yu (Seoul, KR)

Non-vitamin K antagonist oral anticoagulants in comparison to phenprocoumon in a real-word setting of atrial fibrillation: an analysis of a large german health claims dataset

Speaker: Mr C. Hohmann (Cologne, DE)

Dabigatran-induced esophagitis after radiofrequency catheter ablation

Speaker: Doctor Y. Ito (Tsukuba, JP)

Epicardial application of amiodarone-releasing hydrogel: experimental study

Speaker: Professor O. Bockeria (Moscow, RU)

Access the full session

Drug treatment in patients with arrhythmia

Speakers: Ms C. Clausen, Mr G. Brobert, Doctor H. Yu, Mr C. Hohmann, Doctor Y. Ito...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources